Search This Blog

Thursday, June 11, 2026

ActBlue CEO Pleads The Fifth During House Panel Hearing

 by Darlene McCormick Sanchez via The Epoch Times,

ActBlue CEO Regina Wallace-Jones invoked the Fifth Amendment on Wednesday before the House Administration Committee, surrounding reports that she may have misled Congress about how the platform vets foreign donations.

Wallace-Jones had originally agreed to testify voluntarily before Congress concerning ActBlue's vetting process for foreign contributions to domestic candidates. But her attorneys requested a congressional subpoena on Monday, ahead of her June 10 testimony, according to committee lawmakers.

The House asked Wallace-Jones to testify after a recent New York Times report included memos from Covington & Burling, a law firm that worked for ActBlue, warning that she may have misled Congress about the process for screening overseas donations.

ActBlue is the dominant Democratic fundraising platform. In 2025 alone, the platform reported raising almost $1.8 billion from 52 million contributions, and Q4 that year marked the single-largest off-cycle quarter in ActBlue history.

Under federal election law, foreign nationals or those who are not permanent residents are forbidden to donate directly to federal candidates or political action committees.

Administration Committee Chairman Bryan Steil (R-Wis.) said only Americans should decide their elections during the hearing titled, "Preventing Fraudulent Donations: Transparency, Verification, and Accountability."

"Ms. Wallace-Jones is here today because there's a significant concern that ActBlue may have allowed foreign donations on their platform, lied to Congress, and withheld responsive documents from a congressional subpoena," Steil said. "All three of those actions are illegal."

Steil said Wallace-Jones provided a 2023 letter to Congress stating that ActBlue prevents foreign donations by requiring donors with a foreign address to provide U.S. passport information. If a contribution appears to be from a foreign address, ActBlue contacts the donor to request U.S. passport information. The platform would then refund the contribution if ActBlue was unable to contact the donor.

"The New York Times reported that ActBlue's outside counsel determined those three steps are not always followed," Steil said.

Surrounded by attorneys, Wallace-Jones did not answer any questions posed during the hearing, citing the "attorney-client privilege and my Fifth Amendment rights under the Constitution."

Wallace-Jones wrote an opinion piece in The Washington Post that appeared on the day of her hearing, saying she would invoke her Fifth Amendment "rights against self-incrimination."

"This is a proceeding designed to build an illegitimate criminal case against us. I cannot and will not let my words be misused in that way," she opined.

Democrats on the committee called the hearing political theater and questioned why the Republican fundraising platform, WinRed, wasn't receiving equal scrutiny from Republicans.

"We're here because Republicans want to talk about ActBlue, not because they're serious about strengthening campaign finance laws or actually strengthening the abuse of fraud in this country," said Rep. Robert Garcia (D-Calif.), ranking member of the Oversight and Government Reform Committee.

Administrative Committee ranking member Joe Morelle (D-N.Y.) said Republicans are ignoring alleged problems with WinRed. He accused the platform of victimizing elderly Americans.

Morelle also requested a subpoena for Republican Texas Senate candidate Ken Paxton, who, as Texas attorney general, sued ActBlue in state court on April 20. The lawsuit alleged that the platform misleads consumers by illegally accepting fraudulent foreign donations for federal and state candidates.

ActBlue filed a countersuit on May 1 in the U.S. District Court for the District of Massachusetts, seeking to block Paxton's lawsuit. Attorneys for the platform asked a federal judge to declare Paxton's ongoing ActBlue investigation and lawsuit unconstitutional, alleging violations of the First and Fourteenth Amendments.

ActBlue accused Paxton of escalating his investigation after donations for James Talarico, his Democratic opponent in the Texas Senate race, surged.

Paxton responded on the day the suit was filed, saying in an X post that ActBlue was "trying to take [him] down."

U.S. Rep. Bryan Steil (R-Wis.) speaks at a hearing with the House Administration subcommittee on Elections in Washington on June 24, 2021. Anna Moneymaker/Getty Images
https://www.zerohedge.com/political/actblue-ceo-pleads-fifth-during-house-panel-hearing

Purple Bio New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity

 


Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window


Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safety profile compared to the non-capped variant


IM1240 demonstrated anti-tumor activity across PD-1- and chemotherapy-resistant patient-derived tumor samples in head and neck, bladder, and lung cancers, with the NKG2A arm identified as a key contributor to this anti-tumor efficacy

IM1240 induced immune cell structures associated with effective anti-tumor responses and a favorable prognosis in patient-derived non-small cell lung cancer (NSCLC) explants

Liquidia Presents at PHA 2026 Pulmonsry Confab

 Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that the company will present four posters at the PHA 2026 International PH Conference and Scientific Sessions taking place June 11-14 in Dallas.

Liquidia will present data from Cohort A of its ASCENT study of YUTREPIA® (treprostinil) inhalation powder, including patient-reported cough outcomes in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) over 24 weeks of treatment. The company will also present new data and analyses examining the role of pharmacists within PH care teams and the mental health burden experienced by caregivers of patients with PH. In addition, Liquidia will present an encore of previously reported safety and exploratory efficacy data from the ASCENT study.

Dr. Rajeev Saggar, Liquidia Chief Medical Officer, said: “We are proud to share our research with the patients and caregivers at the center of the pulmonary hypertension community. From listening to patients describe their own experience with treatment to understanding the burden carried by caregivers and the role of the care teams who support them, this work reflects our commitment to the people living with this condition every day.”

All posters will be presented from 4 to 5 p.m. CDT Thursday, June 11, in the exhibition hall. Upon presentation, each publicly presented poster will be available on the publications page of Liquidia’s website at https://liquidia.com/publications.


https://finviz.com/news/361184/liquidia-announces-poster-presentations-at-the-pha-2026-international-ph-conference-and-scientific-sessions

Shoulder Innovations: Goldman Sachs Healthcare Conference presentation catalyzes

 

Goldman Sachs Healthcare Conference presentation catalyzes 16.78% SI surge

  • Management presented at June 9 conference in Miami, likely highlighting strong growth.
  • Builds on May Q1 results: 65% YoY revenue growth to $16.7M, raised 2026 outlook to $65-68M.
  • Positive investor meetings and updated insights on shoulder arthroplasty market drove buying.
  • Stock rose from ~$15.32 levels to close at $17.89 on June 10 with elevated volume.
  • Moved alongside other small-cap healthcare names in apparent sector momentum.
  • Conference feedback appears to have extended post-earnings rally from mid-May.

VRXA surges on Nasdaq debut after SPAC merger close with low float

 

VRXA surges 67% on Nasdaq debut after SPAC merger close with low float

  • VERAXA Biotech's business combination with Voyager Acquisition Corp (VACH) closed around June 8-10, 2026.
  • June 10 press release announced trading under VRXA (and VRXAW warrants) would begin June 11.
  • Extremely high SPAC redemptions (~99.67%) resulted in very low public float, amplifying volatility on first trading day.
  • Biotech hype around VERAXA's novel BiTAC platform for bispecific T-cell engagers and antibody-drug conjugates for cancer added retail interest.
  • Multiple trading halts reported as stock ran sharply higher on momentum and low share supply.
  • Typical pattern for low-float de-SPAC/redemption plays driving outsized first-day gains without new clinical data.

Propanc Biopharma authorizes a $5.0 million share repurchase

Propanc Biopharma authorizes a $5.0 million share repurchase program for its common stock.

https://finviz.com/stock?t=PPCB&p=d

Samsung HQ said to be raided in insider trading probe

 Samsung Electronics Co.'s headquarters in Suwon, South Korea, have been raided as part of an investigation into possible insider trading, the Yonhap news agency reported on Thursday. According to sources with knowledge of the matter, the raid was carried out by investigators from the Seoul Southern District Prosecutors' Office.

The report claimed that 16 people are suspected of using insider information to profit around $2.6 million during Samsung's acquisition of Rainbow Robotics from 2022 to 2024. The list allegedly includes Rainbow Robotics' CEO and CFO.

https://breakingthenews.net/Article/Samsung-HQ-said-to-be-raided-in-insider-trading-probe/66486867